EP300: Getting the Right Drugs Developed and Thinking Different About How to Pay for Them, With Bruce Rector, MD

In this milestone Episode 300, Stacey Richter talks with Bruce Rector, MD, biopharmaceutical policy advisor and health policy lecturer, about how to get the right drugs developed — and how to think differently about paying for them.

WHAT YOU'LL LEARN

✅ Why pharmaceutical companies have historically had little incentive to develop new antibiotics

✅ What orphan drugs are, and how the 1983 Orphan Drug Act reshaped drug development incentives

✅ The difference between "push" incentives (funding R&D costs upfront) and "pull" incentives (guaranteeing demand or revenue after launch)

✅ Why drugs don't behave like normal consumer products when there's no competition for a life-saving treatment

✅ What the "fire extinguisher" model and the subscription model offer as alternative ways to pay for drugs like antibiotics

WHY THIS MATTERS

Dr. Bruce Rector unpacks why the market alone often fails to produce the drugs society needs most, using antibiotics as the clearest case study: when resistant infections are rampant but pharma companies see nowhere to make money on new antibiotics, those drugs simply don't get developed. Push incentives fund research costs; pull incentives guarantee a return once a drug launches; and neither alone is enough. Rector's fire extinguisher and subscription payment models offer a different way to think about compensating pharma for drugs that society needs to have on hand, even if they're rarely used.

=== LINKS ===

🔗 Show Notes with all mentioned links: Episode Page

🔗 Healthcare Industry Acronyms and Terms

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

📺 Subscribe to our YouTube channel

🎤 Listen on Apple Podcasts

🎤 Listen on Spotify

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction.

05:58 What's the issue with innovation in the pharmaceutical space?

06:47 "The problem … everyone talks about is antibiotics."

07:38 What are pharmaceutical companies launching to drive value instead of antibiotics?

08:21 What are orphan drugs? And why is development incentivized for those drugs?

11:56 What are the differences between push incentives and pull incentives?

14:37 "The pharma company is all about how much money [the drug] can make once it hits the market."

16:28 "These contracts, they know once they hit the market, there's billions just waiting for them."

17:17 What are the biggest pull and push incentives in Pharma?

17:40 What are the push and pull incentives with antibiotics?

24:39 What's the fire extinguisher theory in Pharma?